1. Show article details.

    BRIEF-NanoString Says Withdrawing Financial Guidance For Fiscal Year 2020

    Reuters – 4:39 PM ET 04/06/2020

    NanoString Technologies Inc (NSTG): * NANOSTRING PROVIDES COVID-19 BUSINESS UPDATE AND ANNOUNCES CONFERENCE CALL ON THURSDAY MAY 7TH, 2020. * NanoString Technologies Inc (NSTG) - GEOMX DSP ORDERS AND REVENUE IN-LINE WITH PRIOR GUIDANCE. * NanoString Technologies Inc (NSTG) - NCOUNTER INSTRUMENT AND CONSUMABLE REVENUE DISRUPTED BY COVID-19.

  2. Show article details.

    NanoString Provides COVID-19 Business Update and Announces Conference Call on Thursday May 7th, 2020

    Business Wire – 4:01 PM ET 04/06/2020

    GeoMx DSP Orders and Revenue In-Line with Prior Guidance nCounter Instrument and Consumable Revenue Disrupted by COVID-19 NanoString Technologies, Inc. (NSTG), a leading provider of life science tools for discovery and translational research, today announced preliminary operational and financial results for the quarter ended March 31, 2020, and outlined the company’s response to the COVID-19 pandemic ...

  3. Show article details.

    BRIEF-NanoString Technologies Announces Pricing Of Upsized Offering Of $200 Mln Of Convertible Senior Notes

    Reuters – 6:13 AM ET 03/05/2020

    NanoString Technologies Inc (NSTG): * NANOSTRING TECHNOLOGIES ANNOUNCES PRICING OF UPSIZED OFFERING OF $200 MILLION OF CONVERTIBLE SENIOR NOTES. * NANOSTRING TECHNOLOGIES (NSTG) - PRICING OF $200 MILLION 2.625% CONVERTIBLE SENIOR NOTES DUE 2025. * NANOSTRING TECHNOLOGIES (NSTG) - OFFERING OF NOTES WAS UPSIZED FROM AGGREGATE PRINCIPAL AMOUNT OF $175 MILLION Source text for Eikon: Further company coverage:

  4. Show article details.

    NanoString Technologies Announces Pricing of Upsized Offering of $200 Million of Convertible Senior Notes

    Business Wire – 6:00 AM ET 03/05/2020

    NanoString Technologies, Inc. (NSTG), a leading provider of life science tools for translational research, today announced the pricing of $200 million aggregate principal amount of 2.625% convertible senior notes due 2025 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

  5. Show article details.

    BRIEF-NanoString Technologies Says Intends To Offer $175 Mln Of Convertible Senior Notes Due 2025 In A Private Placement

    Reuters – 7:27 AM ET 03/04/2020

    NanoString Technologies Inc (NSTG): * NANOSTRING TECHNOLOGIES ANNOUNCES PROPOSED PRIVATE OFFERING OF $175 MILLION OF CONVERTIBLE SENIOR NOTES. * NANOSTRING TECHNOLOGIES (NSTG) - INTENDS TO OFFER $175 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2025 IN A PRIVATE PLACEMENT.

  6. Show article details.

    NanoString Technologies Announces Proposed Private Offering of $175 Million of Convertible Senior Notes

    Business Wire – 7:21 AM ET 03/04/2020

    NanoString Technologies, Inc. (NSTG), a leading provider of life science tools for translational research, today announced that it intends to offer, subject to market conditions and other factors, $175 million aggregate principal amount of convertible senior notes due 2025 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

  7. Show article details.

    BRIEF-NanoString Forecasts 2020 Total Product And Service Revenue Of $124 To $131 Million

    Reuters – 4:06 PM ET 02/26/2020

    NanoString Technologies Inc (NSTG): * NANOSTRING TECHNOLOGIES RELEASES FOURTH QUARTER AND FULL YEAR 2019 OPERATING RESULTS AND PROVIDES 2020 FINANCIAL OUTLOOK. * QTRLY PRODUCT AND SERVICE REVENUE OF $33.6 MILLION, 42% YEAR-OVER-YEAR GROWTH. * QTRLY NET INCOME PER SHARE, DILUTED $0.61. * SEES 2020 TOTAL PRODUCT AND SERVICE REVENUE OF $124 TO $131 MILLION.

  8. Show article details.

    NanoString Technologies Releases Fourth Quarter and Full Year 2019 Operating Results and Provides 2020 Financial Outlook

    Business Wire – 4:00 PM ET 02/26/2020

    NanoString Technologies, Inc. (NSTG), a leading provider of life science tools for translational research, today reported financial results for the fourth quarter and year ended December 31, 2019.

  9. Show article details.

    NanoString Highlights Groundbreaking Spatial Genomics Research Using Expanding Portfolio of GeoMx High-Plex RNA Atlas Products at 2020 Advances in Genome Biology and Technology (AGBT) Conference

    Business Wire – 6:00 AM ET 02/20/2020

    Presenting Ten Research Studies using the Cancer Transcriptome Atlas to Discover Novel Biomarkers and First Data from Forthcoming Whole Transcriptome Atlas Unveiling GeoMx DSP Roadmap at 2nd Annual Spatial Genomics Summit on Sun February 23rd SEATTLE---- NanoString Technologies, Inc. (NSTG), a leading provider of life science tools for discovery and translational research, today announced ten scientif...

  10. Show article details.

    NanoString to Present at the 40th Annual Cowen Healthcare Conference

    Business Wire – 6:00 AM ET 02/18/2020

    NanoString Technologies, Inc. (NSTG), a leading provider of life science tools for translational research, today announced that the company’s management is scheduled to present at the 40th Annual Cowen Healthcare Conference in Boston. Brad Gray, president and chief executive officer, is scheduled to present on Tuesday, March 3rd, 2020 at 8:00am ET.

  11. Show article details.

    NanoString to Release Fourth Quarter and Fiscal Year 2019 Financial Results and Host Conference Call on Wednesday, February 26, 2020

    Business Wire – 9:00 AM ET 02/10/2020

    NanoString Technologies, Inc. (NSTG), a leading provider of life science tools for translational research, today announced that the Company will release fourth quarter and fiscal year 2019 financial results after the close of the market on Wednesday, February 26, 2020.

  12. Show article details.

    Jounce Therapeutics Presents New Vopratelimab Predictive Biomarker Data Supporting Use in the Upcoming SELECT Trial at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting and Announces Research Collaboration with NanoString Technologies

    GlobeNewswire – 8:00 AM ET 02/06/2020

    - Identification of a predictive biomarker – based on an 18 gene RNA signature and vopratelimab-specific threshold – for the emergence of ICOS hi CD4 T cells that predicted clinical benefit in patients from the ICONIC trial - - Research collaboration established with NanoString (NSTG) to implement biomarker-based patient selection in the Phase 2 SELECT clinical trial -                   - SELECT clini...

  13. Show article details.

    Two Landmark Nature Publications use NanoString’s GeoMx Digital Spatial Profiling to Dissect Mechanisms of Response to Immunotherapy

    Business Wire – 1:28 PM ET 01/15/2020

    Deep Molecular Profiling of Immune Cells Critical for Survival and Response to Therapy in Patients with Metastatic Melanoma NanoString Technologies, Inc. (NSTG), a leading provider of life science tools for translational research, today announced the publication of two peer-reviewed studies using the GeoMx™ Digital Spatial Profiler in the journal Nature.

  14. Show article details.

    BRIEF-Nanostring Says Sees FY 2019 Revenue About $125.7 Mln

    Reuters – 6:10 PM ET 01/12/2020

    NanoString Technologies Inc (NSTG): * NANOSTRING PROVIDES PRELIMINARY OPERATIONAL AND FINANCIAL RESULTS FOR FOURTH QUARTER AND FY 2019. * SEES FY 2019 REVENUE ABOUT $125.7 MILLION. * SEES Q4 2019 REVENUE ABOUT $36.6 MILLION Source text for Eikon: Further company coverage:

  15. Show article details.

    NanoString Provides Preliminary Operational and Financial Results for Fourth Quarter and FY 2019

    Business Wire – 6:00 PM ET 01/12/2020

    — FY19 Product and Service Revenue of $103.7 million, including GeoMx DSP Revenue of $10.8 million, Exceeds High End of Guidance Ranges —. — Over 90 Cumulative GeoMx DSP Orders as of Year End —. NanoString Technologies, Inc. (NSTG), a leading provider of life science tools for translational research, today provided preliminary operational and financial results for the fourth quarter and fiscal year en...

Page:

Today's and Upcoming Events

  • May
    07

    NSTG to announce Q1 earnings (Confirmed)

Past Events (last 90 days)

  • Feb
    26

    NSTG announced Q4 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.